Videos

Refractory Hepatocellular Carcinoma

Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.

Cynthia X. Ma, MD, PhD discusses the challenges with understanding treatment duration for adjuvant endocrine therapy in patients with breast cancer.

Ryan Sullivan, MD, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with&nbsp;<em>BRAF V600</em>&ndash;mutant unresectable or metastatic melanoma.

Winston Tan, MD, discusses the work of the Florida Society for Clinical Oncology, which helps improve the treatment of patients with all cancers.

Paul A. Bunn, Jr., MD, discusses subsets of patients with lung cancer that can benefit more from enrolling on clinical trials with immunotherapy compared with patients who do not benefit as much from immunotherapeutic approaches. Immunotherapy does not work in every patient, Bunn notes.

George Sledge, Jr., MD, discusses the overall survival data of the phase III MONARCH-2 trial in advanced hormone receptor-positive, HER2-negative breast cancer.

David S. Hong, MD, discusses&nbsp;updated data with larotrectinib (Vitrakvi) in&nbsp;<em>TRK</em>&nbsp;fusion-positive solid tumors at the ESMO Congress 2019.&nbsp;

Robert L. Coleman, MD, FACOG, FACS, discusses&nbsp;the results of the phase III VELIA trial in patients with advanced ovarian cancer.&nbsp;

Michael Wang, MD, discusses the potential role for the next-generation Bruton&#39;s tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Christopher Sweeney, MBBS, professor of medicine, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the treatment-related adverse events associated with adding enzalutamide or non-steroidal anti-androgens to testosterone suppression treatment and docetaxel in patients with metastatic hormone-sensitive prostate cancer, as seen in the ENZAMET trial.<br /> &nbsp;

Gulam A. Manji, MD, PhD, discusses the need to identify mutations that may be actionable in patients with colorectal cancer. The identification of such mutations can further impact patient survival and improve efficacy, says Manji, in both CRC and other gastrointestinal cancers.

David J. Pinato, MD, PhD, discusses the approach to selecting the appropriate frontline agent for patients with hepatocellular carcinoma. Sorafenib has been around for many years, but now that lenvatinib is FDA approved as well, physicians can now choose between the 2 agents.

Ruben Mesa, MD, discusses his experience with fedratinib since its FDA approval for the treatment of patients with myelofibrosis. The agent is compared across trials with ruxolitinib, which has been approved for several years in this space.

Amol K. Narang, MD, discusses the unanswered questions that still need to be addressed to further expand the role of stereotactic body radiation therapy in gastrointestinal cancers.

Amit Singal, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma and how the treatments differ among patients caught in early-stage versus late-stage at the 2019 International Liver Cancer Association Annual Conference.

Richard S. Finn, MD, discusses the considerations he makes when selecting frontline treatment for patients with advanced hepatocellular carcinoma.

Robert Dreicer, MD, discusses the role of biomarkers to predict response to immunotherapy in patients with urothelial carcinoma. He highlights the current status of using PD-L1 expression as a predictive biomarker to immunotherapy.

Andrew Turk, MD, discusses the main factors that can be used to determine whether a patient presenting with thyroid cancer has an indolent form of the disease or a more aggressive thyroid cancer.

Prostate Cancer

Gail Roboz, MD, discusses the use of FLT3 inhibitors as treatment of patients with acute myeloid leukemia, which can be a heterogenous and difficult-to-treat disease. There is a lot of optimism for new drugs and targets in AML, but the disease itself remains tough to treat, according to Roboz.

Timothy F. Burns, MD, PhD, discusses the necessary role of next-generation sequencing testing in patients with lung adenocarcinoma. In order to incorporate this into clinical practice, there is still a lot more work to be done, Burns says. Around 20% to 25% of patients with adenocarcinoma have targetable alterations.